BMRN
Price
$56.12
Change
-$1.01 (-1.77%)
Updated
Nov 5 closing price
Capitalization
10.86B
111 days until earnings call
Intraday BUY SELL Signals
VRDN
Price
$28.55
Change
-$0.51 (-1.75%)
Updated
Nov 5 closing price
Capitalization
3.23B
126 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

BMRN vs VRDN

BMRN vs VRDN Comparison Chart in %
View a ticker or compare two or three
VS
BMRN vs. VRDN commentary
Nov 06, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BMRN is a Hold and VRDN is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for BMRN with price predictions
Nov 04, 2026

BMRN's MACD Histogram just turned positive

The Moving Average Convergence Divergence (MACD) for BMRN turned positive on October 20, 2026. Looking at past instances where BMRN's MACD turned positive, the stock continued to rise in 33 of 50 cases over the following month. The odds of a continued upward trend are 66%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where BMRN's RSI Indicator exited the oversold zone, 18 of 30 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 60%.

The Momentum Indicator moved above the 0 level on November 04, 2026. You may want to consider a long position or call options on BMRN as a result. In 54 of 85 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 64%.

Following a +4.48% 3-day Advance, the price is estimated to grow further. Considering data from situations where BMRN advanced for three days, in 162 of 280 cases, the price rose further within the following month. The odds of a continued upward trend are 58%.

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 45 of 65 cases where BMRN's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 69%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BMRN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 62%.

BMRN broke above its upper Bollinger Band on October 29, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for BMRN entered a downward trend on October 19, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 1 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 57 (best 1 - 100 worst), indicating steady price growth. BMRN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is 89 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of 98 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.718) is normal, around the industry mean (2.904). BMRN's P/E Ratio (151.676) is considerably higher than the industry average of (-0.738). Projected Growth (PEG Ratio) (0.348) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.314) among similar stocks. P/S Ratio (3.727) is also within normal values, averaging (440.869).

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BMRN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

A.I.Advisor
a Summary for VRDN with price predictions
Nov 04, 2026

VRDN sees its 50-day moving average cross bullishly above its 200-day moving average

The 50-day moving average for VRDN moved above the 200-day moving average on November 03, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 19, 2026. You may want to consider a long position or call options on VRDN as a result. In 68 of 80 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 85%.

The Moving Average Convergence Divergence (MACD) for VRDN just turned positive on October 15, 2026. Looking at past instances where VRDN's MACD turned positive, the stock continued to rise in 30 of 41 cases over the following month. The odds of a continued upward trend are 73%.

VRDN moved above its 50-day moving average on October 20, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for VRDN crossed bullishly above the 50-day moving average on October 28, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 8 of 11 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 73%.

Following a +2.95% 3-day Advance, the price is estimated to grow further. Considering data from situations where VRDN advanced for three days, in 211 of 257 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.

Bearish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 7 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 12 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where VRDN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.

VRDN broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for VRDN entered a downward trend on October 19, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. VRDN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 38 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.734) is normal, around the industry mean (2.904). P/E Ratio (-8.397) is within average values for comparable stocks, (-0.738). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.314) among similar stocks. P/S Ratio (30.488) is also within normal values, averaging (440.869).

The Tickeron Profit vs. Risk Rating rating for this company is 71 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VRDN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.

The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron PE Growth Rating for this company is 92 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

FUNDAMENTALS RATINGS
BMRN vs VRDN: Fundamental Ratings
BMRN
VRDN
OUTLOOK RATING
1..100
944
VALUATION
overvalued / fair valued / undervalued
1..100
98
Overvalued
38
Fair valued
PROFIT vs RISK RATING
1..100
10071
SMR RATING
1..100
8998
PRICE GROWTH RATING
1..100
5736
P/E GROWTH RATING
1..100
192
SEASONALITY SCORE
1..100
8585

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

VRDN's Valuation (38) in the Biotechnology industry is somewhat better than the same rating for BMRN (98). This means that VRDN’s stock grew somewhat faster than BMRN’s over the last 12 months.

VRDN's Profit vs Risk Rating (71) in the Biotechnology industry is in the same range as BMRN (100). This means that VRDN’s stock grew similarly to BMRN’s over the last 12 months.

BMRN's SMR Rating (89) in the Biotechnology industry is in the same range as VRDN (98). This means that BMRN’s stock grew similarly to VRDN’s over the last 12 months.

VRDN's Price Growth Rating (36) in the Biotechnology industry is in the same range as BMRN (57). This means that VRDN’s stock grew similarly to BMRN’s over the last 12 months.

BMRN's P/E Growth Rating (1) in the Biotechnology industry is significantly better than the same rating for VRDN (92). This means that BMRN’s stock grew significantly faster than VRDN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BMRNVRDN
RSI
ODDS (%)
Bullish Trend 2 days ago
60%
Bearish Trend 2 days ago
80%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
69%
Bearish Trend 2 days ago
80%
Momentum
ODDS (%)
Bullish Trend 2 days ago
64%
Bullish Trend 2 days ago
85%
MACD
ODDS (%)
Bullish Trend 2 days ago
66%
Bullish Trend 2 days ago
73%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
60%
Bullish Trend 2 days ago
82%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
64%
Bullish Trend 2 days ago
83%
Advances
ODDS (%)
Bullish Trend 7 days ago
58%
Bullish Trend 8 days ago
82%
Declines
ODDS (%)
Bearish Trend 3 days ago
62%
Bearish Trend 14 days ago
83%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
61%
Bearish Trend 2 days ago
73%
Aroon
ODDS (%)
Bearish Trend 2 days ago
60%
Bearish Trend 2 days ago
88%
COMPARISON
Comparison
Nov 06, 2026
Stock price -- (BMRN: $57.13 vs. VRDN: $29.06)
Brand notoriety: BMRN and VRDN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BMRN: 104% vs. VRDN: 509%
Market capitalization -- BMRN: $10.86B vs. VRDN: $3.23B
BMRN [@Biotechnology] is valued at $10.86B. VRDN’s [@Biotechnology] market capitalization is $3.23B. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $137.5B. The average market capitalization across the [@Biotechnology] industry is $2.27B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BMRN’s FA Score shows that 1 FA rating(s) are green while VRDN’s FA Score has 0 green FA rating(s).

  • BMRN’s FA Score: 1 green, 4 red.
  • VRDN’s FA Score: 0 green, 5 red.
According to our system of comparison, VRDN is a better buy in the long-term than BMRN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BMRN’s TA Score shows that 4 TA indicator(s) are bullish while VRDN’s TA Score has 6 bullish TA indicator(s).

  • BMRN’s TA Score: 4 bullish, 4 bearish.
  • VRDN’s TA Score: 6 bullish, 5 bearish.
According to our system of comparison, VRDN is a better buy in the short-term than BMRN.

Price Growth

BMRN (@Biotechnology) experienced а +2.02% price change this week, while VRDN (@Biotechnology) price change was +19.72% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -8.72%. For the same industry, the average monthly price growth was -14.23%, and the average quarterly price growth was -21.13%.

Reported Earning Dates

BMRN is expected to report earnings on Feb 24, 2027.

VRDN is expected to report earnings on Mar 11, 2027.

Industries' Descriptions

@Biotechnology (-8.72% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
PEJ69.432.48
+3.70%
Invesco Leisure and Entertainment ETF (PEJ)
FSGS33.770.44
+1.31%
First Trust SMID Growth Strength ETF (FSGS)
ZNOV28.250.11
+0.39%
Innovator 1 Yr November (ZNOV)
NYF52.220.19
+0.37%
iShares New York Muni Bond ETF (NYF)
EEV12.41-0.23
-1.80%
ProShares UltraShort MSCI Emerging Markets (EEV)